The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2017 | Individualising treatment for elderly MM patients
Maria-Victoria Mateos, MD, PhD, from the University Hospital of Salamenca, Salamenca, Spain, talks to us about the importance of individualising treatment for elderly patients with multiple myeloma (MM), whose population is highly heterogenous due to variations in their degree of fitness and frailty. She describe that as the median age of diagnosis of MM is over 65 years, treatment for MM is most relevant in the elderly population. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
